{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:03:50Z","timestamp":1781701430368,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2004,3,29]],"date-time":"2004-03-29T00:00:00Z","timestamp":1080518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,3,29]],"date-time":"2004-03-29T00:00:00Z","timestamp":1080518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,5,1]]},"DOI":"10.1038\/sj.bmt.1704472","type":"journal-article","created":{"date-parts":[[2004,3,29]],"date-time":"2004-03-29T09:07:55Z","timestamp":1080551275000},"page":"1005-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia"],"prefix":"10.1038","volume":"33","author":[{"given":"P","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Shahjahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A I","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Karandish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Onida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Beran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,3,29]]},"reference":[{"key":"BF1704472_CR1","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J et al. World Health Organization classication of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting \u2013 Airlie house, Virginia, November 1997. J Clin Oncol 1999; 17: 3835\u20133849.","journal-title":"J Clin Oncol"},{"key":"BF1704472_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF01715120","volume":"65","author":"E Montefusco","year":"1992","unstructured":"Montefusco E, Alimena G, Coco L et al. Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 1992; 65: 17\u201321.","journal-title":"Ann Hematol"},{"key":"BF1704472_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0889-8588(18)30494-5","volume":"4","author":"HM Kantarjian","year":"1990","unstructured":"Kantarjian HM, Kurzrock R, Talpaz M . Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Hematol\/Oncol Clin N Am 1990; 4: 389\u2013404.","journal-title":"Hematol\/Oncol Clin N Am"},{"key":"BF1704472_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1046\/j.1365-2141.2002.03884.x","volume":"119","author":"J Hessling","year":"2002","unstructured":"Hessling J, Kroger, Werner M et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769\u2013772.","journal-title":"Br J Haematol"},{"key":"BF1704472_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","volume":"57","author":"D Przepiorka","year":"1998","unstructured":"Przepiorka D, Giralt S, Khouri I et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24\u201328.","journal-title":"Am J Hematol"},{"key":"BF1704472_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","volume":"98","author":"JE Anderson","year":"1997","unstructured":"Anderson JE, Sale G, Appelbaum FR et al. Allogeneic marrow transplantation for primary myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010\u20131016.","journal-title":"Br J Haematol"},{"key":"BF1704472_CR7","first-page":"743","volume":"16","author":"S Singhal","year":"1995","unstructured":"Singhal S, Powles R, Treleaven J et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16: 743\u2013746.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704472_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","volume":"14","author":"JE Anderson","year":"1996","unstructured":"Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220\u2013226.","journal-title":"J Clin Oncol"},{"key":"BF1704472_CR9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.1987.5.11.1822","volume":"5","author":"MR O'Donnell","year":"1987","unstructured":"O'Donnell MR, Nademanee AP, Snyder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987; 5: 1822\u20131826.","journal-title":"J Clin Oncol"},{"key":"BF1704472_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1046\/j.1365-2141.1997.3073124.x","volume":"98","author":"P Guardiola","year":"1997","unstructured":"Guardiola P, Esperou H, Cazals-Hatem D et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 1997; 98: 1004\u20131009.","journal-title":"Br J Haematol"},{"key":"BF1704472_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562\u20131568.","journal-title":"J Clin Oncol"},{"key":"BF1704472_CR12","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704472_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BF1704472_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD . The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541\u2013554.","journal-title":"Biometrics"},{"key":"BF1704472_CR15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013\u20131018.","journal-title":"Blood"},{"key":"BF1704472_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0950-3536(98)80037-1","volume":"11","author":"JT Reilly","year":"1998","unstructured":"Reilly JT . Pathogenesis and management of idiopathic myelofibrosis. Bailliere's Clin Haematol 1998; 11: 751\u2013767.","journal-title":"Bailliere's Clin Haematol"},{"key":"BF1704472_CR17","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood.V67.6.1693.1693","volume":"67","author":"J Rajantie","year":"1986","unstructured":"Rajantie J, Sale GE, Deeg HJ et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 1986; 67: 1693\u20131697.","journal-title":"Blood"},{"key":"BF1704472_CR18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.1992.tb06958.x","volume":"82","author":"GJ Creemers","year":"1992","unstructured":"Creemers GJ, Lowenberg B, Hagenbeek A . Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 1992; 82: 772\u2013773.","journal-title":"Br J Haematol"},{"key":"BF1704472_CR19","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood.V86.12.4667.bloodjournal86124667","volume":"86","author":"E Soll","year":"1995","unstructured":"Soll E, Massumoto C, Clift RA et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667\u20134673.","journal-title":"Blood"},{"key":"BF1704472_CR20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida F, Kantarjian HM, Smith TL et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840\u2013849.","journal-title":"Blood"},{"key":"BF1704472_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","volume":"6","author":"P Fenaux","year":"1998","unstructured":"Fenaux P, Beuscart R, Lai JL et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1998; 6: 1417\u20131424.","journal-title":"J Clin Oncol"},{"key":"BF1704472_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","volume":"64","author":"A Tefferi","year":"1989","unstructured":"Tefferi A, Hoagland HC, Therneau TM, Pierre RV . Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64: 1246\u20131254.","journal-title":"Mayo Clin Proc"},{"key":"BF1704472_CR23","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","volume":"88","author":"E Wattel","year":"1996","unstructured":"Wattel E, Guerci A, Hecquet B et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480\u20132487.","journal-title":"Blood"},{"key":"BF1704472_CR24","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","volume":"88","author":"M Beran","year":"1996","unstructured":"Beran M, Kantarjian H, O\u2019Brien S et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473\u20132479.","journal-title":"Blood"},{"key":"BF1704472_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1046\/j.1365-2141.2000.02133.x","volume":"110","author":"DY Zang","year":"2000","unstructured":"Zang DY, Deeg HJ, Gooley T et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110: 217\u2013222.","journal-title":"Br J Haematol"},{"key":"BF1704472_CR26","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330\u20131340.","journal-title":"N Engl J Med"},{"issue":"1","key":"BF1704472_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/asheducation-2001.1.375","volume":"2001","author":"R. F. Storb","year":"2001","unstructured":"Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Progr) 2001; 375\u2013391.","journal-title":"Hematology"},{"key":"BF1704472_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1365-2141.2000.02196.x","volume":"111","author":"R Champlin","year":"2000","unstructured":"Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18\u201329.","journal-title":"Br J Haematol"},{"key":"BF1704472_CR29","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","volume":"99","author":"SM Devine","year":"2002","unstructured":"Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255\u20132258.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704472","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:43:39Z","timestamp":1648079019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,29]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["BF1704472"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704472","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,29]]},"assertion":[{"value":"14 February 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}